Isepamicin versus amikacin for the treatment of acute pyelonephritis in children.

[1]  D. Vidyasagar,et al.  Pharmacokinetics of once-daily dosing of gentamicin in neonates. , 1997, The Journal of pediatrics.

[2]  D. Shlaes,et al.  The most frequent aminoglycoside resistance mechanisms--changes with time and geographic area: a reflection of aminoglycoside usage patterns? Aminoglycoside Resistance Study Groups. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  R. Hatala,et al.  Once-Daily Aminoglycoside Dosing in Immunocompetent Adults , 1996, Annals of Internal Medicine.

[4]  K. Shaw,et al.  The changing nature of aminoglycoside resistance mechanisms and the role of isepamicin--a new broad-spectrum aminoglycoside. The Aminoglycoside Resistance Study Groups. , 1995, Journal of chemotherapy.

[5]  R. Colucci,et al.  The susceptibility patterns of the most common Staphylococcus coagulase-negative species to 13 antimicrobials. , 1995 .

[6]  P. L. D. Rosal.  The efficacy and safety of isepamicin compared with amikacin in the treatment of intra-abdominal infections. , 1995 .

[7]  H. Ishikawa,et al.  Clinical evaluation of cefpodoxime proxetil in patients with dermatological infections. , 1995, Journal of chemotherapy.

[8]  G. Beaucaire.  Evaluation of the efficacy and safety of isepamicin compared with amikacin in the treatment of nosocomial pneumonia and septicaemia. , 1995, Journal of chemotherapy.

[9]  V. Leblond,et al.  Isepamicin once daily plus ceftriaxone versus amikacin plus ceftriaxone in febrile neutropenic patients. , 1995, Journal of chemotherapy.

[10]  N. Principi,et al.  A randomised comparison of isepamicin and amikacin in the treatment of bacterial infections in paediatric patients. , 1995, Journal of chemotherapy.

[11]  R. Jones.  Isepamicin (SCH 21420, 1-N-HAPA gentamicin B): microbiological characteristics including antimicrobial potency of spectrum of activity. , 1995, Journal of chemotherapy.

[12]  W. Sturm.  Isepamicin versus amikacin in the treatment of urinary tract infection. , 1995, Journal of chemotherapy.

[13]  G. Heimann,et al.  ONCE DAILY AMINOGLYCOSIDE DOSING IN FULL TERM NEONATES , 1995, The Pediatric infectious disease journal.

[14]  K. Shaw,et al.  The most frequently occurring aminoglycoside resistance mechanisms--combined results of surveys in eight regions of the world. The Aminoglycoside Resistance Study Groups. , 1995, Journal of chemotherapy.

[15]  S. Kondo.  [Development of arbekacin and synthesis of new derivatives stable to enzymatic modifications by methicillin-resistant Staphylococcus aureus]. , 1994, The Japanese Journal of Antibiotics.

[16]  K. Shaw,et al.  Resistance to aminoglycoside antibiotics in gram-negative bacilli and staphylococci isolated from blood. Report from a European collaborative study. The ESGAR Study Group (European Study Group on Antibiotic Resistance). , 1990, The Journal of antimicrobial chemotherapy.

[17]  G. Mccracken.  Arninoglycoside toxicity in infants and children , 1986 .

[18]  A. Cooper,et al.  The syntheses and biological properties of 1-N-(S-4-amino-2-hydroxybutyryl)-gentamicin B and 1-N-(S-3-amino-2-hydroxypropionyl)-gentamicin B. , 1978, The Journal of antibiotics.